UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 328

Sortiert nach

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Clinical infectious diseases, 2024-03

2024

Volltextzugriff (PDF)

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

AIDS reviews, 2019-01, Vol.21 (1), p.4-10

2019

Volltextzugriff (PDF)

Prevention of Anal Cancer

The New England journal of medicine, 2022-08, Vol.387 (7), p.666

2022

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

The Lancet (British edition), 2018-03, Vol.391 (10123), p.839-849

2018

Volltextzugriff (PDF)

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Nature medicine, 2010-04, Vol.16 (4), p.460-465

2010

Volltextzugriff (PDF)

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The New England journal of medicine, 2015-08, Vol.373 (9), p.795-807

2015

Volltextzugriff (PDF)

Time to get serious with HIV-1 resistance in sub-Saharan Africa

The Lancet infectious diseases, 2017-03, Vol.17 (3), p.241-243

Llibre, Josep M

2017

Volltextzugriff (PDF)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Clinical infectious diseases, 2023-02, Vol.76 (4), p.720-729

2023

Volltextzugriff (PDF)

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Clinical infectious diseases, 2021-10, Vol.73 (7), p.e1964-e1972

2021

Volltextzugriff (PDF)

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Clinical infectious diseases, 2015-08, Vol.61 (3), p.403-408

2015

Volltextzugriff (PDF)

Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities

Clinical infectious diseases, 2023-05, Vol.76 (9), p.1655-1657

2023

Volltextzugriff (PDF)

Game-changing study of second-line HIV treatment

The lancet HIV, 2022-06, Vol.9 (6), p.e368-e369

Llibre, Josep M

2022

Volltextzugriff (PDF)

Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial

The Lancet infectious diseases, 2021-10, Vol.21 (10), p.1365-1372

2021

Volltextzugriff (PDF)

Practical measures for SARS-CoV-2 infection prevention – Authors' reply

The Lancet infectious diseases, 2022-01, Vol.22 (1), p.21-21

2022

Volltextzugriff (PDF)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

PloS one, 2016-05, Vol.11 (5), p.e0155406

2016

Volltextzugriff (PDF)

Abacavir and cardiovascular disease: A critical look at the data

Antiviral research, 2016-08, Vol.132, p.116-121

2016

Volltextzugriff (PDF)

Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019

The Journal of infectious diseases, 2022-09, Vol.226 (5), p.938-940

2022

Volltextzugriff (PDF)

Laboratory Report of HIV-1 Low-Level Viremia

Open forum infectious diseases, 2024-02, Vol.11 (2), p.ofad667-ofad667

2024

Volltextzugriff (PDF)

Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study

Clinical infectious diseases, 2020-07, Vol.71 (2), p.390-399

2020

Volltextzugriff (PDF)

A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World

BioMed research international, 2019-01, Vol.2019, p.6057028-11

2019

Volltextzugriff (PDF)

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Frontiers in immunology, 2022-04, Vol.13, p.904689-904689

2022

Volltextzugriff (PDF)

Development of darunavir over the entire spectrum of HIV infection

Enfermedades infecciosas y microbiologia clinica (English ed.), 2018-12, Vol.36 Suppl 2, p.3-9

Llibre, Josep M

2018

Volltextzugriff (PDF)

Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression

Journal of antimicrobial chemotherapy, 2022-05, Vol.77 (6), p.1738-1740

2022

Volltextzugriff (PDF)

Fanconi Syndrome and Tenofovir Alafenamide

Annals of internal medicine, 2019-10, Vol.171 (8), p.598

2019

Volltextzugriff (PDF)

Desarrollo de darunavir en todo el espectro de la infección por el VIH

Enfermedades infecciosas y microbiología clínica, 2018-12, Vol.36, p.3-9

Llibre, Josep M

2018

Volltextzugriff (PDF)

1 – 25 von 328

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(285)
Mit Volltextzugriff
(282)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

Prevention of Anal Cancer

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

Time to get serious with HIV-1 resistance in sub-Saharan Africa

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities

Game-changing study of second-line HIV treatment

Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial

Practical measures for SARS-CoV-2 infection prevention – Authors' reply

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

Abacavir and cardiovascular disease: A critical look at the data

Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019

Laboratory Report of HIV-1 Low-Level Viremia

Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study

A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Development of darunavir over the entire spectrum of HIV infection

Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression

Fanconi Syndrome and Tenofovir Alafenamide

Desarrollo de darunavir en todo el espectro de la infección por el VIH

Suchergebnisse filtern